Benitec Biopharma Inc. key statistics and ratios
In fiscal 2024, Benitec Biopharma Inc. had return on equity of -91.7%, debt equal to 0.0% of equity and a current ratio of 10.49. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2019Jun 2019 | 2020Jun 2020 | 2021Jun 2021 | 2022Jun 2022 | 2023Jun 2023 | 2024Jun 2024 | LTMMar 2025 |
|---|---|---|---|---|---|---|---|
| Operating margin | 21.2% | <−999% | <−999% | <−999% | <−999% | — | — |
| Net margin | 21.4% | <−999% | <−999% | <−999% | <−999% | — | — |
| Free-cash-flow margin | 36.0% | <−999% | <−999% | <−999% | <−999% | — | — |
| Return on equity | 15.7% | −61.7% | −91.8% | −159.1% | — | −91.7% | −46.7% |
| Return on assets | 13.6% | −53.7% | −84.2% | −133.1% | −374.9% | −76.8% | −43.0% |
| Asset turnover | 0.63 | 0.01 | 0.00 | 0.01 | 0.01 | — | — |
| Current ratio | 7.10 | 9.52 | 15.05 | 1.90 | 0.94 | 10.49 | 14.80 |
| Debt to equity | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| R&D as % of revenue | 37.4% | >999% | >999% | >999% | >999% | — | — |
| Capital spending as % of revenue | 3.3% | 93.1% | 374.6% | 17.8% | 1.3% | — | — |
| Free cash flow ÷ net income | 168.1% | — | — | — | — | — | — |
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
More: Biotechnology stocks compared, Health Care sector, rankings of US companies